CollPlant Holdings, Ltd.

CollPlant Holdings is a regenerative medicine company whose core technology platform is derived from tobacco plants genetically engineered to produce recombinant human collagen. The company’s commercial products, including its dermal filler and wound care matrix, are manufactured using this plant-based collagen. However, the development and validation of these products involved animal testing. The company’s SEC filings and published research indicate the use of animal models, such as mice and rats, to assess the biocompatibility, safety, and efficacy of its bio-printed tissues and medical devices prior to clinical trials. This reliance on animal testing for product development and regulatory submission places the company within the scope of the animal exploitation exclusion.

While CollPlant’s commercial manufacturing process is plant-based, its research and development pipeline for 3D bioprinted tissues and organs remains predicated on animal experimentation. The company has not published a formal animal testing policy or committed to alternative testing methods for future development.